Drugs / OBI-992
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06480240 | Jun 2024 → Jun 2027 expected | neoplasm | OBI Pharma, Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2025-04-23 | OBI Pharma, Inc | Results OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science. obipharma.com ↗
OBI-992, a cysteine-based TROP2 targeting ADC, demonstrated a differentiated resistance profile compared to benchmark ADCs. |
| 2024-12-31 | OBI Pharma, Inc | Results OBI Pharma's OBI-992 Research Paper Featured on Cover and Selected as a First Disclosure Article in Molecular Cancer Therapeutics Journal obipharma.com ↗
OBI Pharma’s paper, titled “OBI-992, a novel TROP2-targeted antibody-drug conjugate, demonstrates antitumor activity in multiple cancer models ” has been designated as a First Disclosure publication. |
| 2024-08-07 | OBI Pharma, Inc | Regulatory OBI-992 has been approved by US FDA for Orphan Drug Designation for the treatment of gastric cancer obipharma.com ↗
OBI Pharma, a clinical-stage oncology company (4174.TWO), received the notification letter today from US FDA, stating that the request for Orphan Drug Designation of OBI-992 TROP2 ADC for the treatment of gastric cancer, including gastroesophageal junction cancer, has been approved. |
| 2024-04-11 | OBI Pharma, Inc | Results Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform obipharma.com ↗
OBI-992, a novel TROP2 targeting antibody-drug conjugate, displayed excellent antitumor efficacy in various animal models |
| 2024-03-18 | OBI Pharma, Inc | Results OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform. obipharma.com ↗
When evaluated against comparative TROP2 ADCs, OBI-992 demonstrated greater antitumor efficacy, superior PK/PD properties, and a favorable safety profile across various preclinical animal models. |
| 2024-01-03 | OBI Pharma, Inc | Regulatory OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992 obipharma.com ↗
OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992, to conduct a Phase 1/2 study of its novel antibody – drug conjugate (ADC) cancer therapy targeting TROP2. |
All press releases naming this drug 10 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBI-992 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06480240 ↗ |